RediTrex FDA Approval History
Last updated by Judith Stewart, BPharm on July 27, 2020.
FDA Approved: Yes (First approved November 27, 2019)
Brand name: RediTrex
Generic name: methotrexate
Dosage form: /pro/reditrex-injection.html
Company: Cumberland Pharmaceuticals Inc.
Treatment for: Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, Psoriasis
RediTrex (methotrexate) is a folate analog metabolic inhibitor indicated for the management of rheumatoid arthritis (RA), polyarticular juvenile idiopathic arthritis (pJIA), and psoriasis.
- RediTrex is supplied as single-dose pre-filled syringes (in a needle safety device) for once-weekly subcutaneous administration into the abdomen or thigh.
- Common side effects include nausea, stomach pain, indigestion, mouth sores, rash, nasopharyngitis, diarrhea, liver function test abnormalities, vomiting, headache, bronchitis, thrombocytopenia, alopecia, leucopenia, pancytopenia, dizziness, photosensitivity, and burning skin lesions.
Development timeline for RediTrex
| Date | Article |
|---|---|
| Dec 2, 2019 | Approval FDA Approves RediTrex (methotrexate) for Rheumatoid Arthritis, Juvenile Idiopathic Arthritis, and Psoriasis |
Further information
Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.
